https://www.businesswire.com/news/home/20180725005724/en/

SALT LAKE CITY--(BUSINESS WIRE)--Jul 25, 2018--BioUtah issued the following statement from President and CEO, Kelly Slone, regarding passage of the Protect Medical Innovation Act of 2017 (H.R. 184) in the U.S. House of Representatives:

“BioUtah applauds the bipartisan, overwhelming passage yesterday of the Protect Medical Innovation Act of 2017, to permanently repeal the 2.3% excise tax on medical device sales. Continued uncertainty over the tax could hamper investment in the next generation of life-changing medical technology. We’re pleased the House has taken this step. We’re grateful to the entire Utah congressional delegation who voted for the legislation and have consistently pushed for action to end this misguided tax.